

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	Metrika-013	Total Pages	29
First Named Inventor or Application Identifier			TO
Jan W. Pawlak, et al.			PTO 14/06669
Express Mail Label No.	EM 473 396 932 US		

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner
Box Patent Application
Washington, DC 20231

1. <input type="checkbox"/>	Fee Transmittal Form (Submit an original, and a duplicate for fee processing)		
2. <input checked="" type="checkbox"/>	Specification (preferred arrangement set forth below)	[Total Pages	25]
	<ul style="list-style-type: none"> - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure 		
3. <input checked="" type="checkbox"/>	Drawing(s) (35 USC 113)	[Total Sheets	4]
4. Oath or Declaration	[Total Pages		
a. <input type="checkbox"/>	Newly executed (original or copy)		
b. <input type="checkbox"/>	Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed) <i>[Note Box 5 below]</i>		
i. <input type="checkbox"/>	<u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).		
5. <input type="checkbox"/>	Incorporation By Reference (useable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.		
ACCOMPANYING APPLICATION PARTS			
6. <input type="checkbox"/>	Microfiche Computer Program (Appendix)		
7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)			
a. <input type="checkbox"/>	Computer Readable Copy		
b. <input type="checkbox"/>	Paper Copy (identical to computer copy)		
c. <input type="checkbox"/>	Statement verifying identity of above copies		
8. <input type="checkbox"/>	Assignment Papers (cover sheet & document(s))		
9. <input type="checkbox"/>	37 CFR 3.73(b) Statement	<input type="checkbox"/>	Power of Attorney (when there is an assignee)
10. <input type="checkbox"/>	English Translation Document (if applicable)		
11. <input type="checkbox"/>	Information Disclosure Statement (IDS)/PTO-1449	<input type="checkbox"/>	Copies of IDS Citations
12. <input type="checkbox"/>	Preliminary Amendment		
13. <input checked="" type="checkbox"/>	Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i>		
14. <input type="checkbox"/>	Small Entity Statement(s)	<input checked="" type="checkbox"/>	Statement filed in prior application Status still proper and desired
15. <input type="checkbox"/>	Certified Copy of Priority Document(s) (if foreign priority is claimed)		
16. <input checked="" type="checkbox"/>	Other: <u>Patent Application Declaration and Power of Attorney</u>		

17. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information: Provisional Application

Continuation Divisional Continuation-in-part (CIP) of prior application No: 60 / 084,438

18. CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label

or Correspondence address below

(Insert Customer No. or Attach bar code label here)

NAME	Tmothy H. Gens		By: <i>Tmothy H. Gens</i>		
	Trial & Technology Law Group		Reg. No.: 29,153		
ADDRESS	545 Middlefield Road, Suite 220		Date:		
CITY	Menlo Park	STATE	CA	ZIP CODE	94025
COUNTRY	U.S.A.	TELEPHONE	(650) 324-2269	FAX	(650) 324-0178

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

BLOCKING COMPOSITIONS FOR IMMUNOASSAYS

Inventors: Jan W. Pawlak, Victor A. Manneh, John E. Bartz,
Catherine Pawlak, Patrick M. Sexton, Charles P. Zahl, Jr., and Tilden L. Capen-Frederick

5

FIELD OF THE INVENTION

Compositions and processes for qualitative or quantitative one-step, two-site, tag/anti-tag or competitive non-bibulous lateral flow (immunochromatographic) assays for analytes in body fluids including chemically modified proteins as blocking and/or dispersing agents in
10 conjunction with additives eliminating non-specific interference with the detection agents and/or binding partner caused by endogenous polypeptide constituents.

Composition of the chemically modified proteins can be albumins.

Composition of the chemically modified albumins can have altered charge and/or molecular weight.

Process for composition of the chemically modified proteins can be prepared by modification of the nucleophilic groups. The chemical modification of nucleophilic groups in albumins can be introduced by anhydrides, alkyl acetimidates, methylating and/or cross-linking agents.

The additives eliminating non-specific interference can be chemically modified albumins, heterophilic blockers and chaotropic agents.

BACKGROUND OF THE INVENTION

Compositions and processes designed for one-step lateral flow (immunochromatographic) immunoassays described in prior art (e.g. EP 0 284 232 A1, EP 0 291 25 194 B1, US 4,861,711, EP 0 299 428 Bi, US 5,591,645, US 5,712,170, PCT WO 91/12336, PCT WO 88/08534, PCT WO 94/23300) do not provide for specific and sensitive immunoassays using whole blood/serum specimens in particular.

30

SUMMARY OF THE INVENTION

Compositions and processes for qualitative or quantitative one-step, two-site, tag/anti-tag or competitive non-bibulous lateral flow (immunochromatographic) assays for analytes in body fluids including chemically modified proteins as blocking and/or dispersing agents in conjunction with additives eliminating non-specific interference with the detection agents and/or binding partner caused by endogenous polypeptide constituents.

Composition of the chemically modified proteins can be albumins.

Composition of the chemically modified albumins can have altered charge and/or molecular weight.

Process for composition of the chemically modified proteins can be prepared by modification of the nucleophilic groups. The chemical modification of nucleophilic groups in albumins can be introduced by anhydrides, alkyl acetimides, methylating and/or cross-linking agents.

The additives eliminating non-specific interference can be chemically modified albumins, heterophilic blockers and chaotropic agents.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Example 1

To activate the labeling beads, one ml of 0.403 um Dark Blue latex particles (MPs; P/N 10012; Metrika, Inc., Sunnyvale, CA) at 10% (w/v) solids are combined with 1 ml of 0.5 M MES buffer (pH 6.0), 5.5 ml of deionized H₂O, 2.3 ml of 50 mg of N-hydroxysuccinimide (NHS; Product # 24500; Pierce Chemical Company, Rockford, IL) per ml deionized H₂O and 0.2 ml of 5 mg of 1-ethyl-3-(3-dimethylamino- propyl)carbodiimide hydrochloride (EDC; Product # 22980; Pierce Chemical Company) in deionized H₂O. The resultant mixture is sonicated on ice for 40 seconds and then allowed to react on a shaker at RT for 30 minutes. The activated MPs are then centrifuged at 10°C at 10,000xg and washed three times with cold 50 mM MES buffer (pH 6.0) by resuspension and centrifugation cycles. In a typical procedure, the final pellet of MPs is suspended in 3.666 ml of 50 mM MES buffer (pH 6.0), a 5 ml mixture of 0.6-1.2 mg antigen-specific antibody such as e.g. goat anti-Troponin I peptide 3 antibody (Product code # G-129-C; BiosPacific/Fortron Bio Science Inc., Emeryville, CA, or Product # 9099A; HTI Bio-Products,

Inc., Ramona, CA) and 2.5 mg of mouse IgG (cat. I-8765; Sigma Chemical Company, St. Louis, MO) in the same buffer are added with mixing, followed by an addition of 5 ml of 0.1 M borate buffer (pH 8.5). The mixture is allowed to incubate at RT for 2 hr and then centrifuged as described above. Subsequently, 10 ml of 50 mM borate buffer (pH 8.5) containing 5 mM 5 ethanolamine (cat. # E-9508; Sigma Chemical Company) is added to the pellet, MPs are suspended, incubated at RT for 30 min, and the suspension is centrifuged as described above. The remaining hydrophobic sites on MPs are then blocked with FSG blocking solution composed of 0.1 % (w/v) of fish skin gelatin (FSG; cat. # G-7765; Sigma Chemical Company) in 50 mM borate buffer (pH 8.5) at RT for 30 min. The MPs blocked with FSG are centrifuged as 10 described above and suspended in 0.2 M EPPS buffer (pH 8.0) containing 0.5 % (w/v) of FSG, 0.5 % (w/v) of Hammarsten casein (Product # 440203H; BDH Laboratory Supplies, Poole, England), 0.5 % (v/v) of Tween 20 (cat. # P-1379; Sigma Chemical Company) and 0.01 % (w/v) 15 of NaN₃.

To prepare the capture zone membrane, nitrocellulose having a pore size of >5 um (Product # AE98; Schleicher and Schuell, Keene, NH) is affixed to an XY-plotter table. A Streptavidin-BSA (bovine serum albumin) capture band is dispensed in a 2.0 mm zone at the distal end of the nitrocellulose membrane using Streptavidin-BSA conjugate (e.g. L/N 97-02-20 154; Metrika, Inc.) at 0.85-2.0 mg/ml. The solution is dispensed with an IVEK Digispense (IVEK Corporation, Springfield, VT) dispensing system. After air drying at 45°C, the membrane is placed into a tray containing the membrane blocking solution for 20 minutes at RT. The membrane blocking solution comprises of 0.2-0.35 % (w/v) of poly(vinyl alcohol) (PVA; 80 % hydrolyzed; Av. Mol. Wt. 9,000-10,000; Cat. # 36,062-7; Aldrich Chemical Company, Inc., Milwaukee, WI), 0.5 % (v/v) BSA (Pentex code # 82-045-1; Bayer Corporation, Kankakee, IL) and 0.1 % (w/v) of FSG. The membrane is removed and blotted for 5 minutes. The membrane is 25 air dried at 45°C for 5 minutes, and then placed at less than 5.0 % RH overnight. Processed capture membranes remain at less than 5.0 % RH until assembly.

Serum samples were drawn at Metrika, Inc. from the twenty-four apparently healthy asymptomatic donor volunteers. The specimens were then analyzed by Behring Opus Plus Troponin I Reference Quantitative Assay (Behring cat # 703-050 and 703-006) and/or by Dade

Stratus® Cardiac Troponin-I Fluorometric Enzyme Assay (Dade cat # B5700-64) and they were found to be negative for Troponin I.

For “wet” assays for Troponin I, a 14 X 100 mm strip of the capture zone membrane is affixed centrally on an adhesive opaque strip. The opaque backing is a 23 X 100 mm strip of ARCare mylar made adhesive with 3M 9502. The absorbent--which is a 10 X 100 mm rectangle of Whatman 31ET cellulose paper (Whatman, Inc., Fairfield, NJ)--is affixed distal to the capture zone pad with 0.5 mm overlap. The sample zone pad composed of 7 X 100 mm cellulose acetate (Part # 12301R101X50M; Sartorius Corporation, Santa Clara, CA) is then placed next to the capture zone membrane with 0.5 mm overlap.

Ten-fold concentrated STB for “wet” assays is comprised of 0.5 M EPPS buffer (pH 8.0) supplemented with 6.25 % (v/v) of Tween-20 (cat. P-1379; Sigma Chemical Company), 2 % (w/v) of BSA and 0.1 % (w/v) of NaN₃. In “wet” assays, 9 µl of specimen sample is mixed sequentially in a test tube with 1 µl of 10-fold concentrated stock of STB, 1 µl of biotinylated F(ab')₂ fragment of anti-TnI antibody (e.g. mouse monoclonal antibody against Troponin I; Product # TRI-7F83; Dako Corporation, Carpinteria, CA; or goat anti-Troponin I peptide 69-80; Code # 9099A, HTI Bio-Products, Inc., Ramona, CA) and 1 µl of labeling MPs prepared at 0.5 % (w/v) solids. Subsequently, the “wet” assay strip assembled as just described is placed into the tube, allowed to develop for 7 min, then removed and the intensity of the band is measured with a Gretag reflectance densitometer (Model #D19C; Gretag Color Control Systems, Regensdorf, Switzerland). Increasing values from the Gretag instrument indicate increasing color intensity, which corresponds to increasing analyte concentration.

As shown in Table 1, eleven out of twenty-four serum specimens (46 %) obtained from Troponin I-negative donors gave false positive results in the lateral flow (immunochromatographic) assay.

Table 1. Negative Serum Samples Tested by Metrika TnI Assay

Donor #	Gretag Density Units (GDU)	False Positive Result?
Neg Bovine Calibrator	0.16	No
1	0.97	Yes
2	0.42	Yes
3	0.26	No
4	0.21	No
5	0.22	No
6	0.20	No
7	0.20	No
8	0.29	No
9	0.30	No
10	0.59	Yes
11	0.24	No
12	0.24	No
13	0.92	Yes
14	0.98	Yes
15	0.29	No
16	0.69	Yes
17	0.30	No
18	0.68	Yes
19	0.28	No
20	0.27	No
21	0.77	Yes
22	0.45	Yes
23	1.17	Yes
24	1.01	Yes

Example 2

5 In order to replace the +ve charge on $-\text{NH}^+$, by a -ve charge on the free $-\text{COO}^-$ of the maleyl group, maleic anhydride was reacted with BSA under mildly alkaline conditions. Thus 300 mg of BSA was dissolved at room temperature (RT) in 10 ml of 0.2 M carbonate buffer (pH 8.73), and 122.6 mg of maleic anhydride (cat. # M18-8; Aldrich Chemical Company, 10 Milwaukee, WI) dissolved in 0.5 ml of anhydrous dimethylformamide (DMF; cat. # 27,054-7; Sigma Aldrich Chemical Company) was added with stirring. It should be noted that under those conditions, maleic anhydride also reacts with $-\text{SH}$ groups forming stable derivatives (cf. N-ethylmaleimide). After for 2 hours, 45.3 μl of ethanolamine (cat. # 11,016-7; Aldrich Chemical

Company) was added and allowed to react at RT for 30 min. The resultant reaction mixture was buffer exchanged into 25 mM Tris buffer (pH 8.0) containing 0.1 % (w/v) NaN_3 using Sephadex G-25 Fine resin (cat. # G-25-80; Sigma Chemical Company, St. Louis, MO) to a final concentration of 10 mg/ml.

5 Acetic anhydride (AA) is a reagent of choice for acetylating protein amino groups. At neutral or mildly alkaline pH (7-9.5), AA reacts with unprotonated α - and ϵ - NH_2 groups rendering them electrically neutral. Thus, 2.1g of BSA was dissolved at RT in 70 ml of 0.2 M carbonate buffer (pH 8.7) and 825.7 μl of acetic anhydride (cat. # A-64-4; Sigma Chemical Company) was added with stirring. After for 2 hours, 45.3 μl of ethanolamine was added and 10 allowed to react at RT for 30 min. The resultant reaction mixture was buffer exchanged into 25 mM Tris buffer (pH 8.0) containing 0.1 % (w/v) NaN_3 using Sephadex G-25 Fine resin to a final concentration of 10 mg/ml.

15 Succinic anhydride (SA) reacts preferentially with- NH_2 groups at pH 7-9, converting +ve charge on amino group to a -ve charge; succinyl half-amide derivatives are more stable than maleyl derivatives. Similarly, 150 mg of BSA was dissolved at RT in 5 ml of 0.2 M carbonate buffer (pH 8.7) and 62.56 mg of succinic anhydride (cat. # S-7626; Sigma Chemical Company) dissolved in 250 μl of anhydrous DMF was added with stirring. After for 2 hours, 22.6 μl of ethanolamine was added and allowed to react at RT for 30 min. The resultant reaction mixture was buffer exchanged into 25 mM Tris buffer (pH 8.0) containing 0.1 % (w/v) NaN_3 using Sephadex G-25 Fine resin to a final concentration of 10 mg/ml.

20 Alkyl (e.g. methyl or ethyl) acetimidates react with α - and ϵ - NH_2 groups on proteins at pH 7-10 forming amidine derivatives that retain +ve charge of original amino group, with pK_a of amidine being somewhat higher than that of $-\text{NH}_3^+$. Here, 150 mg of BSA was dissolved at RT in 5 ml of 0.2 M carbonate buffer (pH 8.7), and 77.25 mg of ethyl acetimidate HCl (cat. # E-3880; 25 Sigma Chemical Company) or 68.50 mg of methyl acetimidate HCl (cat. # M-3880; Sigma Chemical Company)--either dissolved in 250 μl of deionized water--was added with stirring. After 2 hours, 22.6 μl of ethanolamine was added and allowed to react at RT for 30 min. The resultant reaction mixture was buffer exchanged into 25 mM Tris buffer (pH 8.0) containing 0.1 % (w/v) NaN_3 using Sephadex G-25 Fine resin to a final concentration of 10 mg/ml.

Low molecular weight product: 990 mg of BSA was dissolved at RT in 30 ml of 0.2 M carbonate buffer (pH 8.7), 242 μ l of formaldehyde (37.3 % solution; cat. G-5250; Sigma Chemical Company) was added with stirring, followed by an addition of 3.33 ml of 1M sodium cyanoborohydride (cat. # 15-615-9; Aldrich Chemical Company) dissolved in the same buffer.

5 After 2 hours, the resultant reaction mixture was buffer exchanged into 25 mM Tris buffer (pH 8.0) containing 0.1 % (w/v) NaN_3 using Sephadex G-25 Fine resin to a final concentration of 10 mg/ml.

High molecular weight product: 57.6 g of BSA was dissolved at RT in 960 ml of 0.2 M carbonate buffer (pH 8.7), and 3.272 ml of glutaraldehyde (Grade I; 25 % aqueous solution; cat. 10 # G-5882; Sigma Chemical Company) was added with stirring, followed by an addition of 96 ml of 1M sodium cyanoborohydride dissolved in the same buffer. After 4 hours, 104 ml of formaldehyde was added with stirring and allowed to react overnight at RT. The reaction was terminated by adding 106 ml of ethanolamine and allowing to react at RT for 30 min. The resultant mixture was exchanged into 50 mM Tris buffer (pH 8.0) containing 0.1 % (w/v) NaN_3 , using Sephadex G-25 Fine resin to a final concentration of 10 mg/ml.

To activate the labeling beads, one ml of 0.403 um Dark Blue latex particles (MPs; P/N 10012; Metrika, Inc) at 10% (w/v) solids are combined with 1 ml of 0.5 M MES buffer (pH 6.0), 5.5 ml of deionized H_2O , 2.3 ml of 50mg of NHS (Product # 24500; Pierce Chemical Company) per ml deionized H_2O and 0.2 ml of 5 mg of EDC (Product # 22980; Pierce Chemical Company) in deionized H_2O . The resultant mixture is sonicated on ice for 40 sec and then allowed to react on a shaker at RT for 30 min. The activated MPs are then centrifuged at 10°C at 10,000xg and washed three times with cold 50 mM MES buffer (pH 6.0) by resuspension and centrifugation cycles. In a typical procedure, the final pellet of MPs is suspended in 3.666 ml of 50 mM MES buffer (pH 6.0), a 5 ml mixture of 0.6-1.2 mg antigen-specific antibody such as e.g. goat anti-25 Troponin I peptide 3 antibody (Product code # G-129-C; BiosPacific/Fortron Bio Science Inc., or Product # 9099A; HTI Bio-Products) and 2.5 mg of mouse IgG (cat. I-8765; Sigma Chemical Company) in the same buffer are added with mixing, followed by an addition of 5 ml of 0.1 M borate buffer (pH 8.5). The mixture is allowed to incubate at RT for 2 hr and then centrifuged as described above. Subsequently, 10 ml of 50 mM borate buffer (pH 8.5) containing 5 mM 30 ethanolamine is added to the pellet, MPs are suspended, incubated at RT for 30 min, and the

suspension is centrifuged as described above. The remaining hydrophobic sites on MPs are then blocked with either (i) FSG blocking solution composed of 0.1 % (w/v) of FSG in 50 mM borate buffer (pH 8.5) at RT for 30 min or (ii) chemically modified BSA solutions described above. The MPs blocked with FSG are centrifuged as described above and suspended in 0.2 M EPPS buffer (pH 8.0) containing 0.5 % (w/v) of FSG, 0.5 % (w/v) of Hammarsten casein, 0.5 % (v/v) of Tween 20 and 0.01 % (w/v) of NaN₃. The MPs blocked with chemically modified BSA solution are centrifuged as described above and suspended in the same solution at 10 mg chemically modified BSA per ml.

To prepare passively coated labeling beads, 0.50 ml of 0.403 um Dark Blue latex particles at 2.5 % (w/v) solids are combined with 0.50 ml of the respective labeling antibody at 1.0 mg/ml in 25 mM Tris buffer (pH 8.0) containing 0.1 % (w/v) NaN₃. The solution is allowed to react passively on an orbital rotator at RT overnight. After centrifugation at 10,000 rpm for 5 minutes, the supernatant is aspirated. The pellet is resuspended in chemically modified BSA solutions described above and MPs are allowed to block for one hour at RT on an orbital rotator. After centrifugation at 10,000 rpm for 5 minutes, the supernatant is aspirated. The pellet is resuspended in chemically modified BSA solution (10 mg/ml) to a final particle concentration of 1.0 % (w/v) solids.

To prepare the alternate capture zone membranes, nitrocellulose having a pore size of >5 μ m is affixed to an XY-plotter table. A Streptavidin-BSA capture band is dispensed in a 2.0 mm zone at the distal end of the nitrocellulose membrane using Streptavidin-BSA conjugate at 0.85-2.0 mg/ml. The solution is dispensed with an IVEK Digispense dispensing system. After air drying at 45°C, the membrane is placed into a tray containing the membrane blocking solution for 20 minutes at RT. The control membrane blocking solution comprises of 0.2-0.35 % (w/v) of PVA. The alternate membrane blocking solutions are chemically modified BSA solutions at 10 mg/ml described above. The membranes are then removed and blotted for 5 minutes. The membranes are air dried at 45°C for 5 minutes, and then placed at less than 5.0 % RH overnight. Processed capture membranes remain at less than 5.0 % RH until assembly.

For alternate “wet” assays for Troponin I, a 14 X 100 mm strip of the capture zone membrane is affixed centrally on an adhesive opaque strip. The opaque backing is a 23 X 100 mm strip of ARCare mylar made adhesive with 3M 9502. The absorbent--which is a 10 X 100

mm rectangle of Whatman 31ET cellulose paper--is affixed distal to the capture zone pad with 0.5 mm overlap. The sample zone pad composed of 7 X 100 mm cellulose acetate is then placed next to the capture zone membrane with 0.5 mm overlap.

5 An alternate Sample Treatment Buffer (STB) for wet assays is "Control" ten-fold concentrated STB for "wet" assays comprised of 0.466 M EPPS buffer (pH 8.0) supplemented with 1 % (w/v) of BSA, 5 % (v/v) of Tween-20 and 0.1 % (w/v) of NaN₃. To test "alternate" STBs, the following stock solutions were prepared: (i) 4 M urea (cat. # U-5128; Sigma Chemical Company) in 0.466 M EPPS buffer (pH 8.0) containing 0.1 % (w/v) of NaN₃; (ii) 5 mg/ml of heterophilic IgG block; (iii) 5-6 mg/ml of goat IgG (cat. # I-5256; Sigma Chemical Company) in 25 mM Tris buffer (pH 8.0) containing 0.1 % (w/v) NaN₃; and (iv) 10.4 mg/ml of non-specific Mouse IgG (Technical Grade; cat. # I-5256; Sigma Chemical Company) in the same buffer.

10 15 20 25 In "wet" assays, 9-10 μ l of specimen sample is mixed sequentially in a test tube with 1 μ l of 10-fold concentrated stock of either "control" or "alternate" STB, 1 μ l of biotinylated F(ab')₂ fragment of anti-TnI antibody (e.g. mouse monoclonal antibody against Troponin I or goat anti-Troponin I peptide 69-80), and 1 μ l of labeling MPs prepared at 0.5 % (w/v) solids,. Subsequently, the "wet" assay strip assembled as just described is placed into the tube, allowed to develop for 7 min, then removed and the intensity of the band is measured with a Gretag reflectance densitometer. Increasing values from the Gretag instrument indicate increasing color intensity, which corresponds to increasing analyte concentration.

25 Serum samples were drawn at Metrika, Inc. from 3 previously identified (Example 1) volunteers whose samples caused severe (donor #1), significant (donor #2) and no (donor #3) interference in the Troponin I lateral flow assay. The specimens were then analyzed by Behring Opus Plus Troponin I Reference Quantitative Assay and/or by Dade Stratus[®] Cardiac Troponin-I Fluorometric Enzyme Assay, and they were found to be negative for Troponin I.

Subsequently, an Opus TnI calibrator (cat. #703-006; Behring Diagnostics Inc., Westwood, MA) was used as an exogenous source of Troponin I which was added to the serum specimens.

Table 2 shows the effectiveness of different blocking reagents at eliminating false positives (FP) and microparticle aggregation caused by serum from Donor #1. None of the blocking reagents tested eliminated false positives or microparticle aggregation.

Table 2. Effect of Different Blocks on False Positives (FP) and Microparticle Aggregation Caused by Serum from Donor #1

Blocking Reagent	Result	
Maleic BSA	Aggregation	FP
Succinylated BSA	Aggregation	FP
Diethylimidated BSA	Aggregation	FP
Dimethylimidated BSA	Aggregation	FP
Bovine IgG	Aggregation	FP
PVA	Aggregation	FP
Acetylated BSA	Aggregation	FP

Table 3 shows the effectiveness of different sample treatment buffer (STB) components at eliminating false positives (FP) and microparticle aggregation (Agg) in serum from three donors and a TnI serum calibrator. The results demonstrate that adding Heteroblock to the STB formulation eliminates FP and Agg in samples negative for TnI. However, when these same samples are spiked with 14.7 ng/mL TnI the microparticles badly aggregate, even in the presence of Heteroblock. This aggregation is resolved by the addition of urea to the STB+Heteroblock mixture. Thus a STB formulation which includes Heteroblock and urea solves the problem of false positives and microparticle aggregation.

Table 3. Effect of Sample Treatment Buffer Upon False Positives (FP) and Microparticle Aggregation (Agg)

With LBB System (cf. Example 1)

Negative Sample	Calibrator		Donor #1		Donor #2		Donor #3	
	FP?	Agg?	FP?	Agg?	FP?	Agg?	FP?	Agg?
STB	no	no			yes	little		
STB+Goat IgG	no	no	yes	little	little	little	no	no
STB+Mouse IgG	no	no	little	little	little	little	no	no
STB+Heteroblock	no	no	no	no	no	no	no	no

14.7 ng/mL Sample

STB	no			
STB+Goat IgG	no			
STB+Mouse IgG	no			
STB+Heteroblock	no	yes	yes	yes
STB+Het+Urea	no			

With AcBSA System (cf. Alternate STB of this example)

Negative Sample	Calibrator		Donor #1		Donor #2		Donor #3	
	FP?	Agg?	FP?	Agg?	FP?	Agg?	FP?	Agg?
STB+Heteroblock	no	no	no	no	no	no	no	no
STB+Het+Urea	no	no	no	no	no	no	no	no

14.7 ng/mL Sample

STB+Heteroblock	no	yes	yes	yes
STB+Het+Urea	no	no	no	no

Example 3

10 To activate the labeling beads, one ml of 0.403 um Dark Blue latex particles at 10% (w/v) solids are combined with 1 ml of 0.5 M MES buffer (pH 6.0), 5.5 ml of deionized H₂O, 2.3 ml of 50mg of NHS per ml deionized H₂O and 0.2 ml of 5 mg of EDC in deionized H₂O. The resultant mixture is sonicated on ice for 40 sec and then allowed to react on a shaker at RT for 30 min. The activated MPs are then centrifuged at 10°C at 10,000xg and washed three times with cold 50 mM MES buffer (pH 6.0) by resuspension and centrifugation cycles. In a typical procedure, the final pellet of MPs is suspended in 3.666 ml of 50 mM MES buffer (pH 6.0), a 5 ml mixture of 0.6-1.2

15

mg antigen-specific antibody such as e.g. goat anti-Troponin I peptide 3 antibody (Product code # G-129-C; BiosPacific/Fortron Bio Science Inc.) and 2.5 mg of mouse IgG in the same buffer is added with mixing, followed by an addition of 5 ml of 0.1 M borate buffer (pH 8.5). The mixture is allowed to incubate at RT for 2 hr and then centrifuged as described above. Subsequently, 10 5 ml of 50 mM borate buffer (pH 8.5) containing 5 mM ethanolamine is added to the pellet, MPs are suspended, incubated at RT for 30 min, and the suspension is centrifuged as described above. The remaining hydrophobic sites on MPs are then blocked with acetylated BSA solutions (10 mg/ml) described above; the pellet is resuspended to a final particle concentration of 0.5 % (w/v) solids.

10 To prepare the capture zone membranes, nitrocellulose having a pore size of >5 um (Part # 11301; Sartorius Corporation) is affixed to an XY-plotter table. A Streptavidin-BSA capture band is dispensed in a 2.0 mm zone at the distal end of the nitrocellulose membrane using Streptavidin-BSA conjugate at 2.57 mg/ml. The solution is dispensed with an IVEK Digispense dispensing system. After air drying at 45°C, the membrane is placed into a tray containing the membrane blocking solution comprised of acetylated BSA solution at 10 mg/ml for 20 minutes at RT. The membranes are then removed and blotted for 5 minutes. The membranes are air dried at 45°C for 5 minutes, and then placed at less than 5.0 % RH overnight. Processed capture membranes remain at less than 5.0 % RH until assembly.

20 For “wet” assays for Troponin I, a 14 X 100 mm strip of the capture zone membrane is affixed centrally on an adhesive opaque strip. The opaque backing is a 23 X 100 mm strip of ARCare mylar made adhesive with 3M 9502. The absorbent--which is a 10 X 100 mm rectangle of Whatman 31ET cellulose paper--is affixed distal to the capture zone pad with 0.5 mm overlap. The sample zone pad composed of 7 X 100 mm cellulose acetate is then placed next to the capture zone membrane with 0.5 mm overlap.

25 Serum samples were collected at The St. Joseph's Hospital, Stockton, CA from patients suspected of myocardial infarction, and the samples were analyzed at the site for Total-CK, CK-MB and Myoglobin levels. Upon receiving, the specimens were analyzed at Metrika, Inc. for Troponin I levels by Behring Opus Plus Troponin I Reference Quantitative Assay, and the respective values were assigned. Table 4 summarizes the just mentioned data.

A Sample Treatment Buffer (STB) for “wet” assays is “Control” 10-fold concentrated STB for “wet” assays comprised of 0.5 M Tris buffer (pH 8.0) supplemented with 10 mg/ml of acetylated BSA, 5 % (v/v) of Tween-20, 0.3-0.6 mg/ml of heterophilic IgG block Heteroblock; P/N 70506; Omega Biologicals Inc., Bozeman, MT), and 0.1 % (w/v) of NaN₃. The following 5 “alternate” STBs were prepared: (i) “control” STB plus 0.5 M Urea; (ii) STB described in (i) supplemented with 5 % (v/v) of bovine serum (cat. # B 8655; Sigma Chemical Company); (iii) 10 50 mM Tris (pH 8.0) containing 10 mg/ml of acetylated BSA, 5% (v/v) bovine serum, 10 µg/ml of purified rabbit skeletal muscle Troponin C (TnC; cat. # T4924, Scripps Laboratories), 150 mM CaCl₂, 0.3-0.6 mg/mL Heteroblock, and 0.1 % (w/v) NaN₃; (iv) STB described in (i) supplemented with 10 µg/ml of purified rabbit skeletal muscle Troponin C and 150 mM CaCl₂; and (v) STB described in (iv) supplemented with 5% bovine serum.

In “wet” assays, 9-10 µl of specimen sample is mixed sequentially in a test tube with 1µl of 10-fold concentrated stock of either “control” or “alternate” STB, 1 µl of biotinylated F(ab')₂ fragment of goat anti-TnI peptide 69-80 antibody (Code # 9099A, HTI Bio-Products, Inc., Ramona, CA) and 1 µl of labeling MPs prepared at 0.5 % (w/v) solids. Subsequently, the “wet” assay strip assembled as just described is placed into the tube, allowed to develop for 7 min, then removed and the intensity of the band is measured with a Gretag reflectance densitometer. Increasing values from the Gretag instrument indicate increasing color intensity, which corresponds to increasing analyte concentration.

20 Figure 1 shows a typical Metrika TnI calibration curve, using STB (ii) including Heteroblock, urea and bovine serum.

Table 4 shows the results of 33 patient samples tested with the Metrika TnI assay and the Behring TnI assay. The Metrika patient samples were tested using STB formulation (ii) including Heteroblock, urea and bovine serum. The raw reflectance density for each sample test strip is 25 recorded as Metrika GDU. This density is converted to clinical ng/mL TnI using the calibration curve in Figure 1, and this clinical value is recorded in the Metrika TnI (ng/mL) column. The Behring Opus TnI assay was used to determine reference values. Figure 2 shows the Metrika and Behring TnI patient sample correlation for the samples in Table 4. Correlation to the Behring TnI assay is 0.928 with a slope of 0.95.

Table 4. Troponin I Patient Sample Results

Patient	Metrika	Metrika	Behring
Sample #	GDU	TnI (ng/mL)	TnI (ng/mL)
46	0.49	23.8	36.6
47	0.22	0.0	0.0
48	0.40	11.5	11.5
49	0.28	2.4	9.8
50	0.47	21.2	31.3
51	0.23	0.0	0.0
52	0.24	0.9	0.0
53	0.57	42.2	37.5
54	0.20	0.0	0.0
55	0.21	0.0	0.0
56	0.60	50.5	41.2
57	0.23	0.0	0.0
59	0.23	0.0	0.8
60	0.22	0.0	0.0
61	0.22	0.0	0.0
62	0.22	0.0	2.0
63	0.24	1.0	0.0
64	0.64	61.2	76.6
65	0.23	0.8	0.0
66	0.23	0.0	0.0
67	0.23	0.8	0.5
68	0.66	68.0	54.6
69	0.22	0.0	0.5
70	0.21	0.0	0.0
71	0.24	0.9	0.9

72	0.22	0.0	0.0
73	0.24	0.9	0.0
74	0.23	0.0	0.0
75	0.21	0.0	0.0
76	0.26	1.5	3.0
77	0.25	1.3	1.9
78	0.22	0.0	0.0
79	0.22	0.0	0.0

Example 4

To verify the effectiveness of the chemically modified BSA blocking solutions in conjunction with the appropriate selection of STB, the quantitative hCG assay was constructed in a lateral flow format.

The sample receiving zone is prepared from Ahlstrom 1281 (Ahlstrom Filtration Inc., Mt. Holly Springs, PA) material. The material is saturated with a blood separating solution at 45 $\mu\text{l}/\text{cm}^2$ containing 2.5 mg/ml rabbit anti-human red blood cells (Code 209-4139; Rockland Immunochemicals, Gilbertsville, PA) antibody diluted in acetylated bovine serum albumin (AcBSA) or methylated BSA (mBSA) prepared at 10 mg/ml. The membrane is frozen at -70° C for at least one hour and then lyophilized in a Virtis Genesis (Virtis, Gardiner, NY) overnight.

The treated sample receiving zone is cut into 7.0 X 7.0 mm squares and stored at less than 5.0 % relative humidity (RH) until assembly.

The sample treatment zone is prepared from Ahlstrom 1281 material. The material is treated with a sample treatment buffer (STB) at 45 $\mu\text{l}/\text{cm}^2$. STB is composed of 0.5M Sodium Perchlorate in 50 mM Tris buffer, 2.0 mg/ml non-specific Mouse IgG (P/N 9902; Intergen Company, Milford, MA), and 1.67 mg/ml heterophilic IgG block. The pad of Ahlstrom 1281 is frozen at -70° C for at least one hour. The Ahlstrom material is lyophilized in the Virtis Genesis overnight. The sample treatment zone is then cut into 3.5 X 3.0 mm rectangles and stored at less than 5.0 % RH until assembly.

To prepare the labeling beads, 0.50 ml of 0.36 um blue latex particles (P/N LC9786; Emerald Diagnostics Inc., Eugene, OR) at 2.5 % solids is combined with 0.50 ml Monoclonal Anti-hCG (clone #5008; Oy Medix Biochemica Ab, Kauniainen, Finland) antibody in 25 mM Tris buffer at 1.0 mg/ml. The solution is allowed to react passively on an orbital rotator at room temperature (RT) overnight. After centrifugation at 10000 rpm for 5 minutes, the supernatant is aspirated. The pellet is resuspended manually with highly polymerized bovine serum albumin (polyBSA) (P/N 99-012-5; Bayer Corporation, Kankakee, IL) solution (10 mg/ml). The particles are allowed to block for one hour at RT on an orbital rotator. After centrifugation at 10,000 rpm for 5 minutes, the supernatant is aspirated. The pellet is resuspended manually with polyBSA solution (10 mg/ml). The particles are allowed to block for one hour at RT on an orbital rotator. After centrifugation at 10,000 rpm for 5 minutes, the supernatant is aspirated. The pellet is resuspended manually with acetylated or methylated BSA solution (10 mg/ml) to a final particle concentration of 1.0 % solids.

To prepare the labeling zone solution, the labeling beads are diluted to a concentration of 0.1 % solids in 10 mg/ml AcBSA or mBSA, prepared in 50 mM Tris buffer, pH 8.0, with 0.1% (w/v) NaN_3 . Sucrose in 50 mM Tris buffer is added to a final concentration of 2.0 %. The resultant mixture is stirred and dispensed onto Whatman F075-14 (Whatman, Inc., Fairfield, NJ) material at 60 $\mu\text{l}/\text{cm}^2$. The material is frozen at -70° C for at least one hour. Membranes are lyophilized in Virtis Genesis overnight. The label containing pads are cut into 3.5 X 3.0 mm rectangles and stored at less than 5.0 % RH until assembly.

To prepare the capture zone membrane, nitrocellulose having a pore size of 8-12 um (Schleicher and Schuell) is affixed to an XY-plotter table. An hCG capture band is dispensed in a 2.0 mm zone at the distal end of the nitrocellulose membrane using Monoclonal Anti-hCG antibody (Clone MC097; Scripps Laboratories, San Diego, CA) at 1.0 mg/ml. The solution is dispensed with an IVEK Digispense dispensing system. After air drying at 45°C, the membrane is placed into a tray containing blocking solution (10 mg/ml AcBSA or mBSA) for 20 minutes at RT. The membrane is removed and blotted for 5 minutes. The membrane is air dried at 45°C for 5 minutes, and then placed at less than 5.0% RH overnight. Processed capture membranes remain at less than 5.0% RH until assembly.

A 3.0 X 7.0 mm strip of the capture zone membrane is affixed centrally on an adhesive opaque strip. The opaque backing is a 350 X 23 mm strip of ARCare mylar made adhesive with 3M 9502.

The pad containing visible label is affixed next to the capture zone pad with 0.5 mm overlap. The sample treatment zone pad is then placed next to the label containing pad with 0.5 mm overlap.

The device is provided with an absorbent, which is a 3.5 X 3.0 mm rectangle of Whatman 31ET (Whatman, Inc.) membrane. It is placed distal to the capture membrane with 0.5 mm overlap.

The resultant test strip on the opaque backing is then placed membrane side down in the MP1 unit such that the sample treatment pad is overlapped by the sample receiving pad by 1.0 mm. The strip is aligned such that the label capturing zones on the capture membrane are visible through the optical aperture of the device. Finally, the top cover is placed together with the bottom casing such that the sample well is aligned over the sample receiving pad.

Biological samples including whole blood, plasma, serum, and urine were collected from healthy, asymptomatic donors. The specimens were analyzed on Dade Stratus® to determine endogenous hCG levels. Analyte was spiked into the specimens at varying concentrations and levels were confirmed on the Reference Quantitative Assay. Quantitative hCG values were assigned and the specimens were assayed as follows:

The device is placed flat on the bench top and 75 ul of sample is applied to the sample receiving zone. The liquid is allowed to flow through the four zones of the assay strip and collect in the absorbent pad. If hCG is present in the sample at least 25 mIU/mL, a blue band in the capture region will appear. The intensity of the band is measured with a Gretag reflectance densitometer. Increasing values from the Gretag indicate increasing color intensity.

The performance of mBSA compared to AcBSA as a blocking reagent in the hCG assay system is shown in Figure 3. The mBSA block gives much better curve separation than the AcBSA block.

Table 5 shows the assay results of 19 different male and female donors that are negative for hCG. None of the samples gave a false positive.

Table 5. Screening of hCG Negative Serum Samples

Donor #	Sex	GDU	FP?
180	f	0.20	No
181	f	0.20	No
184	m	0.20	No
185	m	0.20	No
186	f	0.25	No
187	m	0.20	No
188	m	0.28	No
189	f	0.21	No
190	m	0.20	No
179	m	0.21	No
183	f	0.22	No
191	m	0.22	No
192	f	0.22	No
193	f	0.21	No
194	m	0.19	No
195	f	0.20	No
196	m	0.20	No
197	m	0.21	No
198	m	0.20	No

Metrika-013

Table 6 shows the results of the screening of 14 different donors that tested positive for
5 hCG by the Dade assay. All 14 samples also test positive by the Metrika assay.

Table 6. Screening of hCG Positive Serum Samples

Metrika	Dade
----------------	-------------

Donor #	mIU/mL	Positive?	mIU/mL	Positive?
2	4867	Yes	2965	Yes
5	5911	Yes	3011	Yes
6	1280	Yes	1699	Yes
9	6387	Yes	4905	Yes
52	7009	Yes	6113	Yes
64	7500	Yes	6646	Yes
96	346	Yes	689	Yes
82	4333	Yes	4051	Yes
87	4867	Yes	2740	Yes
83	382	Yes	220	Yes
19	127	Yes	70	Yes
97	155	Yes	86	Yes
91	461	Yes	196	Yes
24	491	Yes	274	Yes

Example 5

Alternate methods for preparation of the streptavidin capture zone for Troponin I assays were tested, utilizing application of biotinylated BSA to nitrocellulose followed by streptavidin solution.

Biotinylated BSA is prepared as follows. BSA is dissolved at 6 mg/ml in 1 ml of 0.1 M sodium phosphate buffer (pH 7.45) and 59 μ l of sulfo-NHS-LC-biotin (EZ Link Sulfo-NHS-LC biotin; product # 21335; Pierce Chemical Company) dissolved at 35 mg/ml of anhydrous DMF is added with stirring at RT. After

1 hr, the reaction mixture is buffer exchanged into 50 mM Tris/HCl buffer (pH 8.0) containing 0.1 % (w/v) NaN_3 using PD-10 columns (code # 17-0851-01; Pharmacia Biotech AB, Uppsala, Sweden).

In the first process (referred to as Process A in Fig. 4 below), nitrocellulose having a pore size of >5 μ m (Schleicher and Schuell) is affixed to an XY table. A biotinylated BSA capture

band is dispensed in a 2.0 mm zone at the distal end of the nitrocellulose membrane using biotinylated BSA at 2.0 mg/ml. The solution is dispensed with an IVEK Digispense dispensing system. The membrane is air dried at 45°C for 15 min and placed into a tray containing the membrane blocking solution comprised of acetylated BSA solution at 10 mg/ml for 20 minutes at RT. The membranes are then removed and blotted for 5 minutes. The membranes are air dried at 45°C for 15 minutes and streptavidin (code # SA10 010; Prozyme, Inc., San Leandro, CA) dissolved at 2 mg/ml in 50 mM Tris/HCl buffer (pH 8.0) containing 0.1 % (w/v) NaN₃ is dispensed with an IVEK Digispense dispensing system. The membranes are then air dried at 45°C for 15 minutes, washed for 5 min with 50 mM Tris/HCl buffer (pH 8.0) containing 0.1 % (w/v) NaN₃. Finally, the membranes are placed again into a tray containing the membrane blocking solution comprised of acetylated BSA solution at 10 mg/ml for 20 minutes at RT. The membranes are then removed and blotted for 5 minutes. The membranes are air dried at 45°C for 15 minutes and then placed at less than 5.0 % RH overnight. Processed capture membranes remain at less than 5.0 % RH until assembly.

In the second process (referred to as Process B in Fig. 4 below), nitrocellulose having a pore size of >5 um (Schleicher and Schuell) is affixed to an XY table. A biotinylated BSA capture band is dispensed in a 2.0 mm zone at the distal end of the nitrocellulose membrane using biotinylated BSA at 2.0 mg/ml. The solution is dispensed with an IVEK Digispense dispensing system. The membrane is air dried at 45°C for 15 min and streptavidin dissolved at 2 mg/ml in 50 mM Tris/HCl buffer (pH 8.0) containing 0.1 % (w/v) NaN₃ is dispensed with an IVEK Digispense dispensing system. The membranes are then air dried at 45°C for 15 minutes, washed for 5 min with 50 mM Tris/HCl buffer (pH 8.0) containing 0.1 % (w/v) NaN₃ and placed into a tray containing the membrane blocking solution comprised of acetylated BSA solution at 10 mg/ml for 20 minutes at RT. The membranes are then removed and blotted for 5 minutes. The membranes are air dried at 45°C for 15 minutes and then placed at less than 5.0 % RH overnight. Processed capture membranes remain at less than 5.0 % RH until assembly.

To activate the labeling beads, one ml of 0.403 um Dark Blue latex particles at 10% (w/v) solids are combined with 1 ml of 0.5 M MES buffer (pH 6.0), 5.5 ml of deionized H₂O, 2.3 ml of 50mg of NHS per ml deionized H₂O and 0.2 ml of 5 mg of EDC in deionized H₂O. The resultant mixture is sonicated on ice for 40 sec and then allowed to react on a shaker at RT for 30

min. The activated MPs are then centrifuged at 10°C at 10,000xg and washed three times with cold 50 mM MES buffer (pH 6.0) by resuspension and centrifugation cycles. In a typical procedure, the final pellet of MPs is suspended in 3.666 ml of 50 mM MES buffer (pH 6.0), a 5 ml mixture of 0.6-1.2 mg antigen-specific antibody such as e.g. goat anti-Troponin I peptide 3 antibody (Product code # G-129-C; BiosPacific/Fortron Bio Science Inc.) and 2.5 mg of mouse IgG in the same buffer is added with mixing, followed by an addition of 5 ml of 0.1 M borate buffer (pH 8.5). The mixture is allowed to incubate at RT for 2 hr and then centrifuged as described above. Subsequently, 10 ml of 50 mM borate buffer (pH 8.5) containing 5 mM ethanolamine is added to the pellet, MPs are suspended, incubated at RT for 30 min, and the suspension is centrifuged as described above. The remaining hydrophobic sites on MPs are then blocked with acetylated BSA solutions (10 mg/ml) described above; the pellet is resuspended to a final particle concentration of 0.5 % (w/v) solids.

For “wet” assays for Troponin I, a 14 X 100 mm strip of the capture zone membrane is affixed centrally on an adhesive opaque strip. The opaque backing is a 23 X 100 mm strip of ARCare mylar made adhesive with 3M 9502. The absorbent--which is a 10 X 100 mm rectangle of Whatman 31ET cellulose paper--is affixed distal to the capture zone pad with 0.5 mm overlap. The sample zone pad composed of 7 X 100 mm cellulose acetate is then placed next to the capture zone membrane with 0.5 mm overlap.

Serum samples were drawn at Metrika, Inc. from apparently healthy asymptomatic volunteers. The specimens were then analyzed by Behring Opus Plus Troponin I Reference Quantitative Assay and/or by Dade Stratus[®] Cardiac Troponin-I Fluorometric Enzyme Assay, and they were found to be negative for Troponin I. Subsequently, a Troponin I+C complex (cat. # T5124; Scripps Laboratories) was used as an exogenous source of Troponin I which was added to the serum specimens.

Ten-fold concentrated STB for “wet” assays comprised of 0.5 M Tris buffer (pH 8.0) supplemented with 10 mg/ml of acetylated BSA, 0.3-0.6 mg/ml of heterophilic IgG block Heteroblock; P/N 70506; Omega Biologicals Inc., Bozeman, MT), 0.1 % (w/v) of NaN₃, 0.5 M Urea, and 5 % (v/v) of bovine serum (cat. # B 8655; Sigma Chemical Company).

In “wet” assays, 10 µl of specimen sample is mixed sequentially in a test tube with 3.4 µl of 10-fold concentrated stock of STB, 1 µl of biotinylated F(ab')₂ fragment of goat anti-TnI

peptide 69-80 antibody (Code # 9099A, HTI Bio-Products, Inc.) and 1 μ l of labeling MPs prepared at 0.5 % (w/v) solids. Subsequently, the “wet” assay strip assembled as just described is placed into the tube, allowed to develop for 10 min, then removed and the intensity of the band is measured with a Gretag reflectance densitometer. Increasing values from the Gretag 5 instrument indicate increasing color intensity, which corresponds to increasing analyte concentration.

Figure 4 shows that Process A is superior to Process B.

WHAT IS CLAIMED IS:

1. A composition and process for a qualitative or quantitative one-step, two-site, tag/anti-tag or competitive non-bibulous lateral flow (immunochromatographic) assays for
5 analytes in body fluids comprising chemically modified proteins for blocking and/or dispersing agents in conjunction with additives eliminating non-specific interference with the detection agents and/or binding partner caused by endogenous polypeptide constituents.

Abstract

Compositions and processes for qualitative or quantitative one-step, two-site, tag/anti-tag or competitive non-bibulous lateral flow (immunochromatographic) assays for analytes in body fluids including chemically modified proteins as blocking and/or dispersing agents in
5 conjunction with additives eliminating non-specific interference with the detection agents and/or binding partner caused by endogenous polypeptide constituents. Composition of the chemically modified proteins can be albumins. Composition of the chemically modified albumins can have altered charge and/or molecular weight. Process for composition of the chemically modified proteins can be prepared by modification of the nucleophilic groups. The chemical modification
10 of nucleophilic groups in albumins can be introduced by anhydrides, alkyl acetimidates, methylating and/or cross-linking agents. The additives eliminating non-specific interference can be chemically modified albumins, heterophilic blockers and chaotropic agents.

Figure 1




Figure 2. Troponin I Patient Sample Correlation, using
SIB Incorporating Heteroblock, Urea, Bovine Serum




Figure 2

Figure 3. mBSA vs. AcBSA Blocking Reagent
in the hCG Assay System




Figure 3

Figure 4. Comparison of Nitrocellulose Striping Sequences
(Streptavidin capture zone)




Figure 4

**DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

BLOCKING COMPOSITIONS FOR IMMUNOASSAYS

the specification of which (check one): is attached hereto.
 was filed on: _____
Application Serial No.: _____
and was amended on: _____

 was described and claimed in
PCT International Application
No. _____
filed on: _____
and as amended under PCT
Article 19 on: _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign or PCT Application(s): Priority Claimed?

Application Number	Country (or indicate if PCT)	Day/Month/Year Filed	[] Yes	[] No
Application Number	Country (or indicate if PCT)	Day/Month/Year Filed	[] Yes	[] No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT International application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

Prior U.S. Application(s) or PCT International Application(s)
Designating the U.S. for Benefit Under 35 USC §120:

U.S. Application Serial No.	U.S. Filing Date	Patented	Pending	Abandoned
60/084,438	5/6/98	x		

U.S. Application Serial No.	U.S. Filing Date	Patented	Pending	Abandoned

PCT Applications Designating the U.S.:

PCT Application No.	PCT Filing Date	U.S. Serial Nos. Assigned (if any)	Patented	Pending	Abandoned

PCT Application No.	PCT Filing Date	U.S. Serial Nos. Assigned (if any)	Patented	Pending	Abandoned

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Stephen E. Baldwin, Reg. No. 27,769
Timothy H. Gens, Reg. No. 29,153
Laurence J. Shaw, Reg. No. 34,723

SEND CORRESPONDENCE TO: Timothy H. Gens, Esq. TRIAL & TECHNOLOGY GROUP 545 Middlefield Road Suite 220 Menlo Park, CA 94025	DIRECT TELEPHONE CALLS TO: (name and telephone number) Timothy H. Gens, Reg. No. 29,153 (650) 324-2269
---	--

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Jan W. Pawlak

Signature: _____ Dated: _____

Residence: 6441 Rolling Meadow Court Citizenship: U.S.A.
San Jose, CA 95135

Post Office Address: Same as above.

Full Name of Inventor: Victor A. Manneh

Signature: _____ Dated: _____

Residence: 1051 Bernardo Avenue Citizenship: U.S.A.
Sunnyvale, CA 94087

Post Office Address: Same as above

Full Name of Inventor: John E. Bartz

Signature: _____ Dated: _____

Residence: 2190 Cuesta Drive Citizenship: U.S.A.
Milpitas, CA 95035

Post Office Address: Same as above.

Full Name of Inventor: Catherine Pawlak

Signature: _____ Dated: _____

Residence: 6441 Rolling Meadow Court Citizenship: U.S.A.
San Jose, CA 95135

Post Office Address: Same as above

Full Name of Inventor: Patrick M. Sexton

Signature: _____ Dated: _____

Residence: 470 Oak Grove Drive, Apt. 313
Santa Clara, CA 95054 Citizenship: U.S.A.

Post Office Address: Same as above.

Full Name of Inventor: Charles P. Zahl, Jr.

Signature: _____ Dated: _____

Residence: 1426 Village Court
Mountain View, CA 94040 Citizenship: U.S.A.

Post Office Address: Same as above.

Full Name of Inventor: Tilden L. Capen-Frederick

Signature: _____ Dated: _____

Residence: 216 Laguna St.
Santa Cruz, CA 95060 Citizenship: U.S.A.

Post Office Address: Same as above